No data to show
OTCM
VPHIF
Market cap4mUSD
Aug 29, Last price
0.05USD
Name
Valeo Pharma Inc
Chart & Performance
P/E
—
P/S
0.12
EPS
—
Div Yield, %
—
Shrs. gr., 5y
12.18%
Rev. gr., 5y
65.20%
Revenues
54m
+94.31%
Net income
-28m
L+8.01%
CFO
-16m
L-44.94%
Earnings
Sep 10, 2025
Profile
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada. Its product portfolio includes Enerzair Breezhaler, an LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, an LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, Idiopathic Parkinson's Disease (PD) as an add-on for patients on stable dose of Levodopa alone or in combination with other drugs; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. In addition, it offers Hesperco, bioflavonoid antioxidant used for immune support; Ametop, for skin Anesthesia prior to venepuncture or venous cannulation; Benztropine, an VPI-Anticholinergic agent used for the treatment of PD; Ethacrynate Sodium, a loop diuretic for high blood pressure and associated swelling; and Amikacin, an injectable antibiotic. The company was incorporated in 2003 and is headquartered in Kirkland, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑10 | 2022‑10 | 2021‑10 | 2020‑10 | 2019‑10 | 2018‑10 | 2017‑10 | 2016‑10 | |
| Income | ||||||||
Revenues | 53,910 94.31% | 27,745 104.65% | ||||||
Cost of revenue | 69,985 | 46,365 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (16,075) | (18,620) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | (1,174) | |||||||
Tax Rate | ||||||||
NOPAT | (16,075) | (17,446) | ||||||
Net income | (27,808) 8.01% | (25,746) 80.89% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 3,920 | 394 | ||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | 4,670 | 794 | ||||||
Long-term debt | 61,903 | 61,812 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | 771 | 127 | ||||||
Net debt | 59,071 | 40,105 | ||||||
| Cash flow | ||||||||
Cash from operating activities | (15,695) | (28,503) | ||||||
CAPEX | (478) | (6,891) | ||||||
Cash from investing activities | (5,553) | (6,891) | ||||||
Cash from financing activities | 6,189 | 54,991 | ||||||
FCF | (15,139) | (21,042) | ||||||
| Balance | ||||||||
Cash | 7,502 | 22,501 | ||||||
Long term investments | ||||||||
Excess cash | 4,806 | 21,114 | ||||||
Stockholders' equity | (50,875) | (28,298) | ||||||
Invested Capital | 76,478 | 72,018 | ||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 86,117 | 80,859 | ||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | (13,449) | (17,202) | ||||||
EV/EBITDA | ||||||||
Interest | 13,790 | 6,461 | ||||||
Interest/NOPBT | ||||||||